BACKGROUND AND OBJECTIVE: The objective of the study was to describe bone loss rates across the transmenopause related to FSH staging and the final menstrual period (FMP). DESIGN AND SETTING: This was a population-based cohort of 629 women (baseline age 24-44 yr) with annual data points over 15 yr. MEASUREMENTS: Measures were bone mineral density (BMD), FSH to define four FSH stages, and menstrual bleeding cessation to define the FMP. Bone loss rates were reported by obesity status. RESULTS: Annualized rates of lumbar spine bone loss began in FSH stage 3, which occurs approximately 2 yr prior to the FMP (1.67%/yr); bone loss continued into FSH stage 4 (1.21%/yr). Mean spine BMD in FSH stage 4 was 6.4% less than spine BMD value in FSH stage 1. Annualized rates of femoral neck (FN) bone loss began in FSH stage 3 (0.55%/yr) and continued into FSH stage 4 (0.72%/yr). The FN difference between mean values in FSH stage 1 and FSH stage 4 was 5%. Annualized rates of spine bone loss in the 2 yr prior to the FMP were 1.7%/yr, 3.3%/yr in the 2 yr after the FMP, and 1.1%/yr in the 2- to 7-yr period after the FMP. Nonobese women had lower BMD levels and greater bone loss rates. CONCLUSIONS: Spine and FN bone loss accelerates in FSH stage 3. Bone loss also began to accelerate 2 yr before the FMP with the greatest loss occurring in the 2 yr after the FMP. Bone loss rates in both spine and FN BMD were greater in nonobese women than obese women.
BACKGROUND AND OBJECTIVE: The objective of the study was to describe bone loss rates across the transmenopause related to FSH staging and the final menstrual period (FMP). DESIGN AND SETTING: This was a population-based cohort of 629 women (baseline age 24-44 yr) with annual data points over 15 yr. MEASUREMENTS: Measures were bone mineral density (BMD), FSH to define four FSH stages, and menstrual bleeding cessation to define the FMP. Bone loss rates were reported by obesity status. RESULTS: Annualized rates of lumbar spine bone loss began in FSH stage 3, which occurs approximately 2 yr prior to the FMP (1.67%/yr); bone loss continued into FSH stage 4 (1.21%/yr). Mean spine BMD in FSH stage 4 was 6.4% less than spine BMD value in FSH stage 1. Annualized rates of femoral neck (FN) bone loss began in FSH stage 3 (0.55%/yr) and continued into FSH stage 4 (0.72%/yr). The FN difference between mean values in FSH stage 1 and FSH stage 4 was 5%. Annualized rates of spine bone loss in the 2 yr prior to the FMP were 1.7%/yr, 3.3%/yr in the 2 yr after the FMP, and 1.1%/yr in the 2- to 7-yr period after the FMP. Nonobese women had lower BMD levels and greater bone loss rates. CONCLUSIONS: Spine and FN bone loss accelerates in FSH stage 3. Bone loss also began to accelerate 2 yr before the FMP with the greatest loss occurring in the 2 yr after the FMP. Bone loss rates in both spine and FN BMD were greater in nonobese women than obesewomen.
Authors: S Fujiwara; M Fukunaga; T Nakamura; J T Chen; M Shiraki; T Hashimoto; K Yoh; T Nakamura; H Mizunuma; T Tomomitsu; F Kasagi; N Masunari; H Orimo Journal: Calcif Tissue Int Date: 1998-09 Impact factor: 4.333
Authors: Sundeep Khosla; B Lawrence Riggs; Richard A Robb; Jon J Camp; Sara J Achenbach; Ann L Oberg; Peggy A Rouleau; L Joseph Melton Journal: J Clin Endocrinol Metab Date: 2005-07-05 Impact factor: 5.958
Authors: Daniel S Perrien; Nisreen S Akel; Paul K Edwards; Adam A Carver; Manali S Bendre; Frances L Swain; Robert A Skinner; William R Hogue; Kristy M Nicks; Tyler M Pierson; Larry J Suva; Dana Gaddy Journal: Endocrinology Date: 2006-12-28 Impact factor: 4.736
Authors: MaryFran R Sowers; Mary Jannausch; Daniel McConnell; Roderick Little; Gail A Greendale; Joel S Finkelstein; Robert M Neer; Janet Johnston; Bruce Ettinger Journal: J Clin Endocrinol Metab Date: 2006-01-10 Impact factor: 5.958
Authors: Daniel S Perrien; Sara J Achenbach; Samuel E Bledsoe; Brandon Walser; Larry J Suva; Sundeep Khosla; Dana Gaddy Journal: J Clin Endocrinol Metab Date: 2006-01-31 Impact factor: 5.958
Authors: Joel S Finkelstein; Sarah E Brockwell; Vinay Mehta; Gail A Greendale; MaryFran R Sowers; Bruce Ettinger; Joan C Lo; Janet M Johnston; Jane A Cauley; Michelle E Danielson; Robert M Neer Journal: J Clin Endocrinol Metab Date: 2007-12-26 Impact factor: 5.958
Authors: Karl J Jepsen; Andrew Kozminski; Erin Mr Bigelow; Stephen H Schlecht; Robert W Goulet; Sioban D Harlow; Jane A Cauley; Carrie Karvonen-Gutierrez Journal: J Bone Miner Res Date: 2017-01-30 Impact factor: 6.741
Authors: S Ishii; J A Cauley; G A Greendale; C J Crandall; M-H Huang; M E Danielson; A S Karlamangla Journal: Osteoporos Int Date: 2013-02-22 Impact factor: 4.507
Authors: Ling-Ling Zhu; Harry Blair; Jay Cao; Tony Yuen; Rauf Latif; Lida Guo; Irina L Tourkova; Jianhua Li; Terry F Davies; Li Sun; Zhuan Bian; Clifford Rosen; Alberta Zallone; Maria I New; Mone Zaidi Journal: Proc Natl Acad Sci U S A Date: 2012-08-20 Impact factor: 11.205
Authors: Carolyn J Crandall; Chi-Hong Tseng; Arun S Karlamangla; Joel S Finkelstein; John F Randolph; Rebecca C Thurston; Mei-Hua Huang; Huiyong Zheng; Gail A Greendale Journal: J Clin Endocrinol Metab Date: 2013-02-26 Impact factor: 5.958